Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230032/S004

AvertD and AvertD Buccal Sample Collection Kit

AutoGenomics, Inc. · Decision date Apr 10, 2026

FDA DECISIONP230032/S004

What did the FDA approve?

FDA records P230032/S004 as a supplement to PMA P230032, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 10, 2026.

FDA approval order statement

Approval for the addition of venous whole blood as sample type for use with the AvertD test.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Clinical Toxicology
Decision date
Apr 10, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230032/S004
Regulatory pathway
PMA supplement
Product code
QZH
Decision code
APPR
Decision date
Apr 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Opioid use disorder genetic risk variant detection system and collection kit.

Product code
QZH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230032/S004 received

    Application receipt date recorded by FDA.

  2. P230032/S003 · Related supplement

    AvertD and AvertD Buccal Sample Collection Kit

  3. P230032/S004 · FDA decision

    Real-Time Process

  4. P230032/S005 · Related supplement

    AvertD and AvertD Buccal Sample Collection Kit

Timeline entries are records held by MedtechLedger for P230032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230032

Product / regulatory recordCompanyPathwayDecision dateSource
AutoGenomics, Inc.PMA supplementJan 29, 2026FDA
AutoGenomics, Inc.PMA supplementMay 20, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

AutoGenomics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1600 Faraday Ave., Carlsbad, CA, 92008

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records